Session Details

F112 Approach to Melanoma Diagnosis

Mon, Mar 11, 1:00 PM - 3:00 PM
Room 1B
2 CME Available Forum
View Map

DESCRIPTION

Open admission to eligible categories, no tuition or ticket

Transitioning to a more patient-centered approach to melanoma detection requires a critical understanding of the current knowledge and issues surrounding the epidemiology of melanoma, precursors of melanoma, and clinical and histologic diagnosis of melanoma as they are related to limitations of the diagnostic gold standard, under- and over diagnosis of melanoma, and advances in molecular diagnostics. Faculty members will present data and analysis of their respective expertise, providing strategies for more optimal management of melanocytic lesions that work toward decreasing the number needed to treat. The session is geared toward all levels of trainees and practicing clinicians.

LEARNING OBJECTIVES

1.

Evaluate the current trends in the epidemiology of melanoma

2.

Recognize the various diagnostic issues of melanoma

3.

Summarize the strategies to achieve a patient-centered approach to melanoma detection

SCHEDULE

8:00 PM

Analysis of risk factors for melanoma incidence and mortality.

8:25 PM

The melanoma epidemic: real of imaginary?

Chauncey A McHargue, MD, FAAD

8:50 PM

Clinical Approach to Melanoma Detection

Jason Bok Lee, MD, FAAD

9:15 PM

Molecular diagnostics to the rescue?

Daniel F Lozeau, MD, FAAD

9:35 PM

Dealing with melanoma overdiagnosis-Can we find an off-ramp?

Robert Swerlick, MD, FAAD

SPEAKERS

Jason Bok Lee, MD, FAAD

Jason Bok Lee, MD, FAAD

Daniel F Lozeau, MD, FAAD

Daniel F Lozeau, MD, FAAD

Chauncey A McHargue, MD, FAAD

Chauncey A McHargue, MD, FAAD

Robert Swerlick, MD, FAAD

Robert Swerlick, MD, FAAD

HANDOUTS

Login to view handouts

SPEAKER DISCLOSURES

Jason Bok Lee, MD, FAAD

No financial relationships exist with ineligible companies.

Daniel F Lozeau, MD, FAAD

No financial relationships exist with ineligible companies.

Chauncey A McHargue, MD, FAAD

No financial relationships exist with ineligible companies.

Robert Swerlick, MD, FAAD

No financial relationships exist with ineligible companies.